The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment.

ABSTRACT: Lung cancer is the leading cause of cancer-related death worldwide, with non-small-cell lung cancer (NSCLC) being the primary type. Unfortunately, it is often diagnosed at advanced stages, when therapy leaves patients with a dismal prognosis. Despite the advances in genomics and proteomics in the past decade, leading to progress in developing tools for early diagnosis, targeted therapies have shown promising results; however, the 5-year survival of NSCLC patients is only about 15%. Low-dose computed tomography or chest X-ray are the main types of screening tools. Lung cancer patients without specific, actionable mutations are currently treated with conventional therapies, such as platinum-based chemotherapy; however, resistances and relapses often occur in these patients. More noninvasive,

SUBMITTER: Abbasian MH 

PROVIDER: S-EPMC9600051 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature